Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Alterity Therapeutics Limited - American Depositary Shares
(NQ:
ATHE
)
4.670
+0.150 (+3.32%)
Streaming Delayed Price
Updated: 3:59 PM EDT, May 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Alterity Therapeutics Limited - American Depositary Shares
< Previous
1
2
3
4
5
6
7
8
Next >
12 Health Care Stocks Moving In Friday's Intraday Session
↗
July 11, 2025
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
July 11, 2025
Via
Benzinga
Why Levi Strauss Shares Are Trading Higher By 8%; Here Are 20 Stocks Moving Premarket
↗
July 11, 2025
Levi Strauss & Co. (NYSE: LEVI) stock rose as Q2 results beat expectations and full-year guidance was raised. Other gainers and losers noted.
Via
Benzinga
Alterity Therapeutics to Provide Corporate Update in Fireside Chat
June 23, 2025
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Prominently Featured at the International MSA Congress
May 12, 2025
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Announces Multiple Oral and Poster Presentations to be Featured at the International MSA Congress
May 07, 2025
ATH434 Phase 2 Data to be Presented at Opening Plenary Session
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
↗
May 05, 2025
Via
Benzinga
Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy
May 05, 2025
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Appendix 4C – Q3 FY25 Quarterly Cash Flow Report
April 30, 2025
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Presents ATH434-201 Phase 2 Clinical Trial Results at European MSA Symposium
April 28, 2025
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Presents Encouraging New Data from its ATH434 Phase 2 Trial in Multiple System Atrophy at the American Academy of Neurology Annual Meeting
April 10, 2025
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics to Deliver an Oral Presentation of the Positive ATH434 Phase 2 Trial Results at the American Academy of Neurology Annual Meeting
April 03, 2025
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Completes Last Patient Visit in ATH434-202 Open-Label Phase 2 Trial in Multiple System Atrophy
March 27, 2025
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Raises A$40.0 million in Placement
February 10, 2025
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Wondering what's happening in today's after-hours session?
↗
February 07, 2025
The US market regular session of Friday is over, let's have a look at the top gainers and losers in the after hours session today.
Via
Chartmill
Nasdaq Moves Lower; Meta Platforms Posts Strong Sales
↗
January 30, 2025
Via
Benzinga
What's Going On With Alterity Therapeutics Shares Thursday?
↗
January 30, 2025
Alterity Therapeutics shares are moving higher on Thursday after the company reported positive topline results from its Phase 2 clinical trial of ATH434 in early-stage multiple system atrophy.
Via
Benzinga
Dow Jumps Over 100 Points; Tesla Earnings Miss Views
↗
January 30, 2025
Via
Benzinga
Topics
Earnings
Stocks
Alterity Therapeutics Stock Doubles Premarket On Positive MSA Trial Results: Retail Excitement Soars
↗
January 30, 2025
A 50mg dose of its ATH434 showed 8% reduction in clinical progression of early-stage multiple system atrophy vs. placebo.
Via
Stocktwits
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
January 30, 2025
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
January 30, 2025
Via
Benzinga
Why Meta Platforms Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
↗
January 30, 2025
Via
Benzinga
Appendix 4C – Q2 FY25 Quarterly Cash Flow Report
January 24, 2025
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones
January 09, 2025
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Completes Last Patient Visit in ATH434-201 Phase 2 Clinical Trial in Early-Stage Multiple System Atrophy
December 04, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
November 29, 2024
Via
Benzinga
Alterity Therapeutics Appoints Abby Macnish Niven as Company Secretary
November 19, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Announces Presentation on Tracking the Progression of Multiple System Atrophy at International Symposium
November 12, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Alterity Therapeutics Announces New Publication Describing Novel Mechanism of Action for ATH434
November 06, 2024
– Peer-Reviewed Publication Describes How ATH434 Uniquely Targets Excess Iron –
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
Appendix 4C – Q1 FY25 Quarterly Cash Flow Report
October 31, 2024
From
ALTERITY THERAPEUTICS LIMITED
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
